Nisa Investment Advisors
PVLA

Nisa Investment Advisors’s Palvella Therapeutics PVLA Stock Holding History

Nisa Investment Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Buy
105
+34
+48% +$4.13K ﹤0.01% 2320
2026
Q1 		$8.85K Hold
71
– – ﹤0.01% 2285
2025
Q4 		$7.43K Buy
+71
New +$6.06K ﹤0.01% 2348

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Nisa Investment Advisors's PVLA Position: Q2 2026 in Review

Nisa Investment Advisors increased its Palvella Therapeutics (PVLA) stake by 48% in Q2 2026, buying an estimated $4.13K and bringing the position to 105 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

Nisa Investment Advisors first reported a position in PVLA in Q4 2025 and has held it in 3 quarters since. 127 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Nisa Investment Advisors held 105 shares of Palvella Therapeutics worth $16K as of Q2 2026.
  • Nisa Investment Advisors bought 34 Palvella Therapeutics shares in Q2 2026, an estimated $4.13K.
  • Palvella Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2320 holding.
  • Nisa Investment Advisors first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 127 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.